Sustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes

Journal of Pathology

Volumn 235, Issue 5, 2015, Pages 686-697

  Hamburg Shields, Emily ^a   Dinuoscio, Gregg J ^a   Mullin, Nathaniel K ^a   Lafayatis, Robert ^b   Atit, Radhika P ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dermis; extracellular matrix; fibroblast; fibrosis; catenin

Indexed keywords

BETA CATENIN; T CELL FACTOR PROTEIN; TRANSCRIPTION FACTOR; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; CTNNB1 PROTEIN, MOUSE; SCLEROPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; COLLAGEN FIBER; COLLAGEN FIBRIL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; MORPHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; UPREGULATION; ANIMAL; DNA MICROARRAY; FIBROBLAST; FIBROSIS; GENE EXPRESSION PROFILING; GENETICS; GENOTYPE; HUMAN; METABOLISM; PATHOLOGY; PROCEDURES; SKIN; TRANSGENIC MOUSE; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; BINDING SITES; EXTRACELLULAR MATRIX PROTEINS; FIBROBLASTS; FIBROSIS; GENE EXPRESSION PROFILING; GENOTYPE; HUMANS; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROMOTER REGIONS, GENETIC; SKIN; TRANSCRIPTION FACTORS; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84924623581     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4481     Document Type: Article

References (70)

1. Bitterman PB, Henke CA,. Fibroproliferative disorders. Chest 1991; 99: 81-84S.
2. Krenning G, Zeisberg EM, Kalluri R,. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010; 225: 631-637.
3. Postlethwaite AE, Shigemitsu H, Kanangat S,. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr Opin Rheumatol 2004; 16: 733-738.
4. Driskell RR, Lichtenberger BM, Hoste E, et al., Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 2013; 504: 277-281.
5. Whitfield ML, Finlay DR, Murray JI, et al., Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-12324.
6. Pendergrass SA, Lemaire R, Francis IP, et al., Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012; 132: 1363-1373.
7. Hinchcliff M, Huang CC, Wood TA, et al., Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol 2013; 133: 1979-1989.
8. Milano A, Pendergrass SA, Sargent JL, et al., Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008; 3: e2696.
9. Russell SB, Russell JD, Trupin KM, et al., Epigenetically altered wound healing in keloid fibroblasts. J Invest Dermatol 2010; 130: 2489-2496.
10. Smith JC, Boone BE, Opalenik SR, et al., Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol 2007; 128: 1298-1310.
11. Denton CP, Zheng B, Evans LA, et al., Fibroblast-specific expression of a kinase-deficient type II transforming growth factor-β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003; 278: 25109-25119.
12. Distler A, Lang V, Del Vecchio T, et al., Combined inhibition of morphogen pathways demonstrates additive antifibrotic effects and improved tolerability. Ann Rheum Dis 2014; 73: 1264-1268.
13. Bhattacharyya S, Wei J, Varga J,. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011; 8: 42-54.
14. Hamburg EJ, Atit RP,. Sustained β-catenin activity in dermal fibroblasts is sufficient for skin fibrosis. J Invest Dermatol 2012; 132: 2469-2472.
15. Akhmetshina A, Palumbo K, Dees C, et al., Activation of canonical Wnt signalling is required for TGFβ-mediated fibrosis. Nat Comm 2012; 3: 735.
16. Beyer C, Schramm A, Akhmetshina A, et al., β-Catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012; 71: 761-767.
17. Surendran K, Schiavi S, Hruska KA,. Wnt-dependent β-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005; 16: 2373-2384.
18. Beyer C, Reichert H, Akan H, et al., Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis 2013; 72: 1255-1258.
19. Cheon SS, Nadesan P, Poon R, et al., Growth factors regulate β-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res 2004; 293: 267-274.
20. Cheon SS, Cheah AYL, Turley S, et al., β-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci USA 2002; 99: 6973-6978.
21. Klapholz-Brown Z, Walmsley GG, Nusse YM, et al., Transcriptional program induced by Wnt protein in human fibroblasts suggests mechanisms for cell cooperativity in defining tissue microenvironments. PLoS One 2007; 2: e945.
22. Archbold HC, Yang YX, Chen L, et al., How do they do Wnt they do? Regulation of transcription by the Wnt/β-catenin pathway. Acta Physiol 2011; 204: 74-109.
23. Tiedemann K, Bätge B, Müller PK, et al., Interactions of fibrillin-1 with heparin/heparan sulfate, implications for microfibrillar assembly. J Biol Chem 2001; 276: 36035-36042.
24. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
25. Huang DW, Sherman BT, Lempicki RA,. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.
26. Huang DW, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
27. Kwon AT, Arenillas DJ, Worsley Hunt R, et al., oPOSSUM-3: advanced analysis of regulatory motif over-representation across genes or ChIP-Seq datasets. G3 2012; 2: 987-1002.
28. Mi H, Muruganujan A, Thomas PD,. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013; 41: D377-386.
29. Mi H, Muruganujan A, Casagrande JT, et al., Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 2013; 8: 1551-1566.
30. Naba A, Clauser KR, Hoersch S, et al., The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteom 2012; 11: M111.014647.
31. Barrett T, Wilhite SE, Ledoux P, et al., NCBI GEO: archive for functional genomics datasets-update. Nucleic Acids Res 2013; 41: D991-995.
32. Edgar R, Domrachev M, Lash AE,. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-210.
33. Huang DW, Sherman BT, Lempicki RA,. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2008; 4: 44-57.
34. Sayers EW, Barrett T, Benson DA, et al., Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2012; 40: D13-25.
35. Mathelier A, Zhao X, Zhang AW, et al., JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles. Nucleic Acids Res 2014; 42: D142-147.
36. Fisher LW, Stubbs JT, Young MF,. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop Scand Suppl 1995; 266: 61-65.
37. Bayle J, Fitch J, Jacobsen K, et al., Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2007; 128: 871-881.
38. Wu TD, Nacu S,. Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 2010; 26: 873-881.
39. Anders S, Pyl PT, Huber W,. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics, btu638.
40. Jho E, Zhang T, Domon C, et al., Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22: 1172-1183.
41. Leask A, Abraham DJ,. TGFβ signaling and the fibrotic response. FASEB J 2004; 18: 816-827.
42. Verrecchia F, Mauviel A, Farge D,. Transforming growth factor-β signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 2006; 5; 563-569.
43. He W, Tan R, Dai C, et al., Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/β-catenin signaling. J Biol Chem 2010; 285: 24665-24675.
44. Hayes RL, Rodnan GP,. The ultrastructure of skin in progressive systemic sclerosis (scleroderma). I. Dermal collagen fibers. Am J Pathol 1971; 63: 433-442.
45. Rockwell WB, Cohen IK, Ehrlich HP,. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstruct Surg 1989; 84: 827-837.
46. Planche A, Bacac M, Provero P, et al., Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS One 2011; 6: e18640.
47. Sulpice L, Rayar M, Desille M, et al., Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013; 58: 1992-2000.
48. Wang XM, Zhang Y, Kim HP, et al., Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006; 203: 2895-2906.
49. Pardo A, Gibson K, Cisneros J, et al., Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005; 2: e251.
50. Meltzer EB, Barry WT, D'Amico TA, et al., Bayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principle. BMC Med Genom 2011; 4: 70.
51. Renzoni EA, Abraham DJ, Howat S, et al., Gene expression profiling reveals novel TGFβ targets in adult lung fibroblasts. Respir Res 2004; 5: 24.
52. Gardner H, Shearstone JR, Bandaru R, et al., Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006; 54: 1961-1973.
53. Schönherr E, Witsch-Prehm P, Harrach B,. Interaction of biglycan with type I collagen. J Biol Chem 1995; 270: 2776-2783.
54. San Martin S, Zorn TMT,. The small proteoglycan biglycan is associated with thick collagen fibrils in the mouse decidua. Cell Mol Biol 2003; 49: 673-678.
55. Wei J, Fang F, Lam AP, et al., Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012; 64: 2734-2745.
56. Sato M., Upregulation of the Wnt/β-catenin pathway induced by transforming growth factor-β in hypertrophic scars and keloids. Acta Derm Venereol 2006; 86: 300-307.
57. Hinz B, Phan SH, Thannickal VJ, et al., Recent developments in myofibroblast biology. Am J Pathol 2012; 180: 1340-1355.
58. Kissin EY, Merkel PA, Lafyatis R,. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006; 54: 3655-3660.
59. Lecca MR, Maag C, Berger EG, et al., Fibrotic response in fibroblasts from congenital disorders of glycosylation. J Cell Mol Med 2011; 15: 1788-1796.
60. Smith GP, Chan ESL,. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr Rheumatol Rep 2010; 12: 26-33.
61. Derrett-Smith EC, Denton CP, Sonnylal S,. Animal models of scleroderma: lessons from transgenic and knockout mice. Curr Opin Rheumatol 2009; 21: 630-635.
62. Lemaire, R, Farina, G, Bayle, J, et al., Antagonistic effect of the matricellular signaling protein CCN3 on TGFβ- and Wnt-mediated fibrillinogenesis in systemic sclerosis and Marfan syndrome. J Invest Dermatol 2010; 130: 1514-1523.
63. Liu J, Krautzberger AM, Sui SH, et al., Cell-specific translational profiling in acute kidney injury. J Clin Invest 2014; 124: 1242-1254.
64. Kalluri R, Zeisberg M,. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
65. Ng TL, Gown AM, Barry TS, et al., Nuclear β-catenin in mesenchymal tumors. Mod Pathol 2005; 18: 68-74.
66. Chilosi M, Poletti V, Zamò A, et al., Aberrant Wnt/β-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003; 162: 1495-1502.
67. Hesselstrand R, Westergren-Thorsson G, Scheja A, et al., The association between changes in skin echogenicity and the fibroblast production of biglycan and versican in systemic sclerosis. Clin Exp Rheumatol 2002; 20: 301-308.
68. Hunzelmann N, Anders S, Sollberg S, et al., Coordinate induction of collagen type I and biglycan expression in keloids. Br J Dermatol 1996; 135: 394-399.
69. Lafyatis R., SSc-fibrosis takes flight with Wingless inhibition. Nat Rev Rheumatol 2012; 8: 441-442.
70. Dees C, Distler JHW,. Canonical Wnt signalling as a key regulator of fibrogenesis-implications for targeted therapies? Exp Dermatol 2013; 22: 710-713.